Estimated generic prices for novel treatments for drug-resistant tuberculosis | Zendy

Dzintars Gotham | Zendy; Joseph Fortunak | Zendy; Anton Pozniak | Zendy; Saye Khoo | Zendy; Graham Cooke | Zendy; Frederick E. Nytko | Zendy; Andrew Hill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Estimated generic prices for novel treatments for drug-resistant tuberculosis

Author(s) -

Dzintars Gotham,

Joseph Fortunak,

Anton Pozniak,

Saye Khoo,

Graham Cooke,

Frederick E. Nytko,

Andrew Hill

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw522

Subject(s) - bedaquiline , moxifloxacin , linezolid , medicine , clofazimine , generic drug , tuberculosis , vancomycin , pharmacology , drug , antibiotics , mycobacterium tuberculosis , biology , staphylococcus aureus , leprosy , genetics , pathology , dermatology , bacteria , microbiology and biotechnology

The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research